Table 1 Demographic and clinical characteristics of the patients (N = 1355)
Variables | N | % |
|---|---|---|
Age, years | ||
 Mean (SD) | 59.7 | SD 12.0 |
 < 60 | 667 | 49.2 |
 ≥ 60 | 688 | 50.8 |
Sex | ||
 Female | 475 | 35.1 |
 Male | 880 | 64.9 |
Clinical T stage | ||
 Tis-T2 | 131 | 9.7 |
 T3/4 | 1211 | 89.4 |
 Tx | 13 | 1.0 |
Clinical N stage | ||
 N0 | 252 | 18.6 |
 N1/2 | 1049 | 77.4 |
 Nx | 54 | 4.0 |
Distance of tumor from the anal verge | ||
 Lower | 559 | 41.3 |
 Middle | 675 | 49.8 |
 Upper | 121 | 8.9 |
Year of diagnosis* | ||
 < 2013 | 511 | 37.7 |
 ≥ 2013 | 844 | 62.3 |
ypT | ||
 Tis/0 | 286 | 21.1 |
 T1/2 | 381 | 28.1 |
 T3/4 | 682 | 50.3 |
 Tx | 6 | 0.4 |
ypN | ||
 N0 | 980 | 72.3 |
 N1/2 | 372 | 27.5 |
 Nx | 3 | 0.2 |
Neoadjuvant chemotherapy | ||
 Capecitabine | 794 | 58.6 |
 FL | 422 | 31.1 |
 Others | 139 | 10.3 |
Adjuvant chemotherapy | ||
 FL | 277 | 20.4 |
 Capecitabine | 230 | 17.0 |
 FOLFOX | 204 | 15.1 |
 Others | 16 | 1.2 |
 None | 628 | 46.3 |
RT modality | ||
 3D-CRT | 851 | 62.8 |
 Tomotherapy | 504 | 37.2 |
RT fractionation | ||
 LCRT | 1325 | 97.8 |
 SCRT | 30 | 2.2 |